Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
2026 China (Shenyang) South Korea Week Held Successfully, Deepening Shenyang-South Korea Exchanges and Cooperation
GlobeNewswire, Inc.
SHENYANG, China, Oct. 08, 2026 (GLOBE NEWSWIRE) -- September 23 witnessed the opening of the 2026 China (Shenyang) South Korea Week. The event was hosted by the Shenyang Municipal People's Government and co-hosted by the Publicity Department of...
Discover a New Side of Busan, South Korea After Dark
EIN Presswire
“Starry Night in Busan” initiative expands nighttime travel with river cruises, local night markets and new waterfront experiences across the city.
“The Carbon Pursuit of Happiness” Premieres October 10: A New Chapter for In-Depth Dialogue on Health and Humanity
GlobeNewswire, Inc.
BEIJING, Oct. 09, 2026 (GLOBE NEWSWIRE) -- “The Carbon Pursuit of Happiness” is co-produced by Phoenix Media Group, Guangzhou Pharmaceutical, and Guangzhou Baiyunshan Pharmaceutical, and will officially premiere on October 10. Using human health...
U.S. Navy Veteran Revisits South Korea Through the Revisit Korea Program
DVIDS - Georgia
COMMANDER FLEET ACTIVITIES, CHINHAE, SOUTH KOREA- U.S. Navy veteran, Dr. Daniel Frenning revisits South Korea through the Revisit Korea Program orchestrated by the Republic of Korea government to thank the service members from the U.S. who have...
Korea F-5 Residency Applications Focus on Fund Compliance and Legal Review
EIN Presswire
Globevisa outlines South Korea's F-5 investment visa rules, focusing on residency requirements, fund compliance, and legal due diligence frameworks.
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
GlobeNewswire, Inc.
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and...
Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
GlobeNewswire, Inc.
Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2 Statistically significant improvements in secondary endpoints of ON time without troublesome dyskinesia and motor experiences of daily...
Warm Breezes and Light Clouds, Time to Recharge: Huangshan Is Emerging as an Oriental Wellness Destination for Young Korean Travelers
GlobeNewswire, Inc.
HUANGSHAN, China, Oct. 06, 2026 (GLOBE NEWSWIRE) -- For young Koreans who live at a fast pace and place increasing value on emotional well-being, meaningful experiences, and sharing travel moments, Huangshan in China is emerging as an appealing...
South Korea's Lee Offers North Korea 'Three Blueprints' for Peace
MENAFN
(MENAFN) South Korean President Lee Jae Myung extended an offer of peace and renewed cooperation to North Korea on Tuesday, calling for dialogue and peaceful coexistence in an address to the 81st session of the UN General Assembly in New York. Lee...
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
GlobeNewswire, Inc.
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate Baseline CSF NfL predicted the rate of functional decline, supporting its use as a...
Principal Guarantee and Exit Paths for the South Korea F2 Investment Visa
EIN Presswire
Explore how South Korea’s principal-guaranteed F2 Visa fund secures HNWI capital.
Seoul Says Kyiv Asked for Secrecy on North Korean POWs First
MENAFN
(MENAFN) South Korea escalated its dispute with Ukraine on Wednesday, insisting that Kyiv broke a confidentiality agreement over the handover of two North Korean prisoners of war (POWs) and that it was Ukraine that first asked for the matter to be...
VSee Launches MorePerfect for Functional Longevity and Healthy Aging Research
EIN Presswire
Unveiled at the 2026 Asia-Pacific Healthy Longevity Summit, it helps patients find clinics and lets researchers compare "body twin" data for precise care.
Pharmazz Completes Enrollment in 160-Patient Phase 4 Trial of Sovateltide in Acute Ischemic Stroke
GlobeNewswire, Inc.
Enrollment completed in the double-blind, placebo-controlled Phase 4 study (NCT05955326) of sovateltide (Tycamzzi®), with final study data expected in Q1 2027 Five sovateltide abstracts accepted at World Stroke Congress, October 21-23, 2026,...
Why Under-Eye Filler Goes Wrong: Cliff Clinic's Dr. Gunwoo Hong Splits Dark Circles Into Three Problems
EIN Presswire
Cliff Clinic's Dr. Gunwoo Hong Separates Dark Circles Into Three Problems at Seoul Forum SEOUL, SOUTH KOREA, October 1, 2026 /EINPresswire.com/ -- At the YAPMS Aesthetic Medicine Innovation Forum, Dr. Hong outlined the three components of dark...
SCAN Builds a New Kind of Medicare Advantage Product Portfolio for 2027 Through Strategic Partnerships, Expanded Markets and Differentiated Benefits
EIN Presswire
LONG BEACH, CA, UNITED STATES, October 2, 2026 /EINPresswire.com/ -- Following a historic Annual Enrollment Period (AEP) in 2026, during which SCAN Health Plan (SCAN), one of the nation’s largest not-for-profit Medicare Advantage (MA) plans,...
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
GlobeNewswire, Inc.
NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1...
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
GlobeNewswire, Inc.
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026 Participants...
Vima Therapeutics to Present New Research at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
GlobeNewswire, Inc.
BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced that four poster presentations will be featured at the 2026 International...
VandS Hair Clinic Sets a New Focus on Post-Transplant Scalp Care
EIN Presswire
Advanced FUE techniques and ongoing academic research shape VandS Hair Clinic’s comprehensive approach to hair transplantation and aftercare.
Sign up for:
Health Daily South Korea
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.